Similarly, the use of SBRT was also less likely than moderate hypofractionation in patients with a higher Gleason score (AOR for >7 vs <7, 0.09 [95% CI, 0.09-0.10]; P < .001), higher PSA level (AOR for >20 vs ≤4 ng/mL, 0.55 [95% CI, 0.50-0.62]; P < .001), higher tumor grade (AOR for T3a-T3b vs T1a-T2a, 0.21 [95% CI, 0.17-0.25]; P < .001), and higher Charlson-Deyo Comorbidity Index score (AOR for ≥3 vs 0, 0.62 [95% CI, 0.52-0.73]; P < .001). This evidence concerns the gene KLK3 and neoplasm.